Imatinib mesylate : A designer drug

Journal of Association of Physicians of India

Volumn 54, Issue MAR., 2006, Pages 203-206

  Panigrahi, Inusha ^a   Naithani, R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOCYTIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; EOSINOPHILIA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PHILADELPHIA 1 CHROMOSOME;

EOSINOPHILIA; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 33645167727     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53.
2. Singhal N, Bapsy PP, Babu KG, George J. Chronic myeloid leukemia. J Assoc Physicians India 2004;52:410-6.
3. Copland M, Fraser AR, Harrison SJ, Holyoake TL. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukemia. Cancer Immunol Immunother 2005;54:297-306.
4. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-42.
5. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;(Epub ahead of print).
6. Peggs K. Imatinib mesylate - gold standards and silver linings. Clin Exp Med 2004;4:1-9.
7. Morishima Y, Ogura M, Nishimura M, et al. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol 2004;80:261-6.
8. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with Interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
9. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-9.
10. Morita R, Hashino S, Sogabe S, et al. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis] Rinsho Ketsueki 2004;45:1105-10
11. Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. J Assoc Physicians India 2005;53:291-5.
12. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005;25:325-34.
13. Kantarjian HM, Bueso-Ramos CE, Talpaz M, et al. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 2005;46:993-7.
14. Pulsipher MA. Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy? Pediatr Blood Cancer 2004;43:523-33.
15. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neo-adjuvant therapy. Ann Surg Oncol 2004;11:465-75.
16. Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother 2005;6:105-13.
17. Kosmadakis N, Visvardis EE, Kartsaklis P, et al. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness. Surg Oncol 2005; (Epub ahead of print).
18. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449-57.
19. Tefferi A, Pardanani A. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. Int J Hematol 2004;79:441-7.
20. Musto P, Falcone A, Sanpaolo G, et al. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hyper eosinophilic syndrome: implications for dosing and pathogenesis. Leuk Lymphoma 2004;45:1219-22.
21. Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Ada Haematol 2005;114:52-60.
22. Choi IK, Kim BS, Lee KA, et al. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t (15; 19): case report. Am J Hematol 2004;77:366-9.
23. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme : a patient series. Ann Oncol 2005; (Epub ahead of print).
24. Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 2005;46:781-4.
25. Prasad N, Deshmukh C, Biswas G, Bakshi A, Sastry PS, Parikh PM. Dermatological toxicity of imatinib mesylate. J Assoc Physicians India 2005;53:298.
26. Yamamoto M, Kakihana K, Kurosu T, Murakami N, Miura O. Clonal evolution with inv (11)(p15q22) and NUP98/ DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia. Cancer Genet Cytogenet 2005;157:104-8.
27. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18:1321-31.
28. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinibresistant mutants. Gastroenterologey 2005;128:270-9.
29. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2005;105:22-30.
30. Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J. Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia 2005; (Epub ahead of print).
31. Chalandon Y, Schwaller J. Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies. Haematologica 2005;90:949-68.